Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4022 | standard care Wiki | 0.50 |
drug739 | Chloroquine Wiki | 0.41 |
drug1472 | Hydroxychloroquine Wiki | 0.10 |
Navigate: Correlations HPO
There is one clinical trial.
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain. A feasibility study of PEX therapy has been undertaken and confirmed a reduction in the inflammatory markers, no VTE/arterial events and normalisation of the renal function and cardiac function throughout the period of therapy. As plasma exchange is an intensive treatment modality, blocks of 5 daily PEX will be undertaken. Further blocks of PEX treatment can be initiated as dictated by the clinical and laboratory parameters. Unlike many therapeutic schedules, there is no immunosuppression associated with PEX; indeed, the resulting decrease in inflammatory markers were shown to be associated with an increase and sustained lymphocytes count.
Description: To compare the change in inflammatory markers with Plasma Exchange and control groups in patients with severe COVID-19
Measure: Change in Inflammatory Marker-CRP Time: 5 daysDescription: To compare the change in inflammatory markers with Plasma Exchange and control groups in patients with severe COVID-19
Measure: Change in Inflammatory Marker-D Dimer Time: 5 DAYSDescription: To compare the change in inflammatory markers with Plasma Exchange and control groups in patients with severe COVID-19
Measure: Change in Inflammatory Marker-LDH Time: 5 DAYSDescription: To compare rates of mechanical ventilation between Plasma Exchange (PEX) and control groups in patients with severe COVID requiring CPAP/ NIV at treatment onset
Measure: Rates of mechanical ventilation Time: 28 daysDescription: To compare rates of clinical thrombotic events either venous (deep vein thrombosis DVT or pulmonary embolism PE) or arterial thrombus (cardiac, neurological and peripheral vascular) between Plasma Exchange (PEX) and control groups in patients with severe Covid-19
Measure: Rates of clinical thrombotic events Time: 28 daysDescription: To compare the change in the inflammatory-thrombotic response by monitoring von Willebrand factor VWFA antigen/ADAMTS 13 activity ratio between Plasma Exchange (PEX) and control groups in patients with severe COVID-19
Measure: Change in inflammatory-thrombotic response Time: 28 daysDescription: To compare the incidence of acute kidney injury as defined by KDIGO criteria between Plasma Exchange (PEX) and control groups in patients with severe COVID-19
Measure: To compare the incidence of acute kidney injury Time: 28 daysDescription: To compare mortality at day 28 between the PEX and control groups
Measure: Mortality at day 28 Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports